Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC)
| Study Name | |
| Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | |
| ClinicalTrials.gov Identifier (if applicable) | |
| NCT04566133 | |
| Clinical Trial Category (check all that apply) | |
|
|
| Study Center | |
| Institution Name | |
| National Cancer Institute | |
| Institution Address | |
| 10 Center Drive | |
| City | |
| Bethesda | |
| State | |
| Maryland | |
| Zip Code | |
| 20892 | |
| Country | |
| United States | |
| Phone | |
| (240) 858-3155 | |
| Website | |
| https://ccr.cancer.gov/staff- |
|
| Study Contacts | |
| Principal Investigator | |
| Tim Greten | |
| P.I. Phone | |
| (240) 760-6114 | |
| P.I. Email | |
| tim.greten@nih.gov | |
| Study Coordinator | |
| Donna Mabry | |
| Study Coordinator Phone | |
| (240) 858-3155 | |
| Study Coordinator Email | |
| donna.mabry@nih.gov | |
| OVERVIEW – in layman’s terms (150 words max) | |
| We test a combination of trametinib and hydroxychloroquine (HCQ) as systemic treatment in patients with KRAS mutated bile duct cancer. Treatment is free at NIH. Travel costs will be paid for. |
|
| Enrollment | |
| open | |
| Study Start Date | |
| 07/15/2021 | |
| Estimated Completion Date | |
| Study completed 12/31/2022 | |
| Purpose of the Study – in Layman’s Terms (use the “+” to add more list items) | |
|
|
| Inclusion Criteria – Patients Must: | |
|
|
| REQUIRED TESTS PRIOR TO BEGINNING STUDY TREATMENT – in layman’s terms | |
|
|